Loading...

David I Quinn, MD

TitleAssociate Professor of Medicine (Clinical Scholar)
InstitutionUniversity of Southern California
DepartmentMedicine
AddressNOR 3453
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3956
vCardDownload vCard
    Other Positions
    TitleSection Head, Genitourinary (Gu) Oncology, Division of Cancer Medicine and Blood Diseases in The Department of Medicine


    Collapse Biography 
    Collapse Awards and Honors
    University of New South Wales1987Gordon Lowe Memorial Prize
    University of New South Wales1987Honours First Class Bachelor of Medicine, Bachelor of Surgery
    National Health and Medical Research Council of Australia1996  - 1999Postgraduate Medical Scholarship
    Postgraduate Medical Council of New South Wales2000Distinguished Contribution Award
    St. Vincent's Clinic Foundation2000The David Wilson Travelling Fellowship
    National Health and Medical Research Council of Australia2000  - 2003Neil Hamilton Fairley Fellowship
    Royal Australasian College of Physicians2001Vincent Fairfax Family Fellowship
    USC Norris Cancer Center and Hospital2002The Spirit of Norris Award
    Castle Connolly Medical2010America's Top Doctors

    Collapse Overview 
    Collapse Overview
    David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

    He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

    Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.


    Collapse Research 
    Collapse Research Activities and Funding
    NCI NCTN- Network Lead Academic Participating Site: USC
    NIH/NCI U10CA180830Apr 17, 2014 - Feb 28, 2019
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Antonarakis ES, Small EJ, Petrylak D, Quinn D, Kibel AS, Chang N, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival. Clin Cancer Res. 2018 Jun 01. PMID: 29858218.
      View in: PubMed
    2. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn D, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Mortazavi A, Vaughn DJ, Isaacs RE, Parker K, Chen X, Yu K, Porter D, Sharma S, Graus Porta D, Bajorin DF. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018 May 30. PMID: 29848605.
      View in: PubMed
    3. Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, Nieva J, Kuhn P, Newton PK. Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clin Biomech (Bristol, Avon). 2018 May 18; 56:61-69. PMID: 29803824.
      View in: PubMed
    4. Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn D, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol. 2018 May 18. PMID: 29784193.
      View in: PubMed
    5. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn D, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 May 20; 36(15):1498-1504. PMID: 29624463.
      View in: PubMed
    6. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 Mar 28; JCO2017769562. PMID: 29590008.
      View in: PubMed
    7. Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn D, Shevrin D, Shore ND, Symanowski JT, Penson DF. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536. PMID: 29417827.
      View in: PubMed
    8. Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn D, Chung E, Abreu A, Hamilton AS. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 Feb 06. PMID: 29483045.
      View in: PubMed
    9. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, Frick G, Friedman B, Graßl T, Ichikawa T, Ioannidis JP, Lacy P, McManus R, Murray A, Myers M, Palatini P, Parati G, Quinn D, Sarkis J, Shennan A, Usuda T, Wang J, Wu CO, O'Brien E. A Universal Standard for the Validation of Blood Pressure Measuring Devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. Hypertension. 2018 Mar; 71(3):368-374. PMID: 29386350.
      View in: PubMed
    10. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn D, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 08; 554(7691):189-194. PMID: 29420467.
      View in: PubMed
    11. Hollar TL, Cook N, Quinn D, Phillips T, DeLucca M. Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. J Immigr Minor Health. 2017 Dec; 19(6):1281-1289. PMID: 27189486.
      View in: PubMed
    12. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn D, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J Nucl Med. 2017 Dec; 58(12):2026-2037. PMID: 29025980.
      View in: PubMed
    13. Pili R, Quinn D, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clin Cancer Res. 2017 Dec 01; 23(23):7199-7208. PMID: 28939740.
      View in: PubMed
    14. Wu M, Ouyang Y, Wang Z, Zhang R, Huang PH, Chen C, Li H, Li P, Quinn D, Dao M, Suresh S, Sadovsky Y, Huang TJ. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci U S A. 2017 Oct 03; 114(40):10584-10589. PMID: 28923936.
      View in: PubMed
    15. Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn D, Dorff TB. Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clin Genitourin Cancer. 2017 Sep 06. PMID: 28958673.
      View in: PubMed
    16. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn D, Lara PN. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. PMID: 28832978.
      View in: PubMed
    17. Gross ME, Dorff TB, Quinn D, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. PMID: 28826933.
      View in: PubMed
    18. Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn D. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. PMID: 28749918.
      View in: PubMed
    19. Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn D, Dorff TB, Xiong S, Engel J, Pinski J. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):742-749. PMID: 28668277.
      View in: PubMed
    20. Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn D. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. PMID: 28749907.
      View in: PubMed
    21. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn D. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 Dec; 15(6):635-641. PMID: 28579151.
      View in: PubMed
    22. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn D, Sadeghi S. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 Jul; 35(7):459.e15-459.e24. PMID: 28284890.
      View in: PubMed
    23. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026. PMID: 28212060.
      View in: PubMed
    24. Barzi A, Lenz HJ, Quinn D, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. PMID: 28117881.
      View in: PubMed
    25. Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. BJU Int. 2017 09; 120(3):401-408. PMID: 27981731.
      View in: PubMed
    26. Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn D, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2017 Feb; 79(2):339-351. PMID: 28058445.
      View in: PubMed
    27. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn D, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76. PMID: 27939400.
      View in: PubMed
    28. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn D, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227.
      View in: PubMed
    29. Ballas LK, de Castro Abreu AL, Quinn D. What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. PMID: 27694176.
      View in: PubMed
    30. Yu SS, Quinn D, Dorff TB. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016; 9:5825-5837. PMID: 27713636.
      View in: PubMed
    31. Penson DF, Lin DW, Karsh L, Quinn D, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. PMID: 27528114.
      View in: PubMed
    32. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn D. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016 06 10; 16:360. PMID: 27282289; PMCID: PMC4901417.
    33. Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn D, Motzer RJ. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016 Jul 20; 34(21):2478-83. PMID: 27185842.
      View in: PubMed
    34. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn D, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 May 10; 34(14):1652-9. PMID: 26951312; PMCID: PMC4872320 [Available on 04/10/17].
    35. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn D, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 01; 34(13):1500-9. PMID: 26926681.
      View in: PubMed
    36. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn D. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 10; 14(5):450-456.e1. PMID: 26935231.
      View in: PubMed
    37. Wu Y, Chen YX, Yan J, Quinn D, Dong P, Sawyer SW, Soman P. Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. Acta Biomater. 2016 Mar; 33:122-30. PMID: 26821341.
      View in: PubMed
    38. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn D, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. PMID: 26771938.
      View in: PubMed
    39. Quinn D, Lara PN. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 05; 373(19):1872-4. PMID: 26406149.
      View in: PubMed
    40. Morgan RJ, Synold TW, Longmate JA, Quinn D, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. PMID: 26362045; PMCID: PMC4694049 [Available on 11/01/16].
    41. Quinn D, Frith D. Assessing the damage control resuscitation: development, drivers and direction. Emerg Med Australas. 2015 Oct; 27(5):485-7. PMID: 26315261.
      View in: PubMed
    42. Dorff TB, Hu J, Quinn D. Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. PMID: 26094170.
      View in: PubMed
    43. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn D, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. PMID: 25847934; PMCID: PMC4417730.
    44. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn D, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr; 16(4):426-35. PMID: 25795408.
      View in: PubMed
    45. Jadvar H, Challa S, Quinn D, Conti PS. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. PMID: 25746633; PMCID: PMC4492702.
    46. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn D, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. PMID: 25711194; PMCID: PMC4834920.
    47. Jadvar H, Groshen SG, Quinn D. Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. PMID: 25625748.
      View in: PubMed
    48. Quinn D, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015 May; 33(5):245-60. PMID: 25575714.
      View in: PubMed
    49. Vashistha V, Quinn D, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014 Dec 16; 14:966. PMID: 25515347; PMCID: PMC4301463.
    50. Ballas LK, Hu BR, Quinn D. Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-21. PMID: 25456359.
      View in: PubMed
    51. Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn D, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. PMID: 25374407.
      View in: PubMed
    52. Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn D, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52. PMID: 25457633.
      View in: PubMed
    53. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn D. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358; PMCID: PMC4323674.
    54. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn D, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. PMID: 25278449.
      View in: PubMed
    55. Alpert BS, Quinn D, Gallick D. Oscillometric blood pressure: a review for clinicians. J Am Soc Hypertens. 2014 Dec; 8(12):930-8. PMID: 25492837.
      View in: PubMed
    56. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One. 2014; 9(8):e105326. PMID: 25148033; PMCID: PMC4141800.
    57. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn D, Dorff TB, Kopchick JJ, Longo VD. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014 Jun 05; 14(6):810-23. PMID: 24905167; PMCID: PMC4102383.
    58. Dorff TB, Hu JS, Quinn D. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. PMID: 25134324.
      View in: PubMed
    59. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn D, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44. PMID: 24840869.
      View in: PubMed
    60. Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn D, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014 Sep 01; 120(17):2684-93. PMID: 24802654; PMCID: PMC4142676.
    61. Quinn D. Skate park injury: a new mechanism of sternoclavicular joint dislocation. Emerg Med Australas. 2014 Jun; 26(3):316-7. PMID: 24712682.
      View in: PubMed
    62. Dart RA, Alpert B, Quinn D. Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation. Blood Press Monit. 2014 Apr; 19(2):120. PMID: 24618886.
      View in: PubMed
    63. Goldkorn A, Ely B, Quinn D, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308; PMCID: PMC3970171.
    64. Rini BI, Quinn D, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2015 Mar; 10(1):45-53. PMID: 24595903; PMCID: PMC4363524.
    65. Lara PN, Ely B, Quinn D, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. PMID: 24565955; PMCID: PMC3982883.
    66. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn D, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. PMID: 24829759; PMCID: PMC4019894.
    67. Quinn D, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. PMID: 24224900.
      View in: PubMed
    68. Dorff TB, Pal SK, Quinn D. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. PMID: 24308791.
      View in: PubMed
    69. Jadvar H, Quinn D. Targeted a-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. PMID: 24212441; PMCID: PMC3874447.
    70. Dorff TB, Wilkins C, Hepgur M, Quinn D. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. PMID: 24331572.
      View in: PubMed
    71. Mitra AP, Skinner EC, Schuckman AK, Quinn D, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52.e1-9. PMID: 24239476.
      View in: PubMed
    72. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn D, Dorff TB. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. PMID: 24238569.
      View in: PubMed
    73. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn D, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
      View in: PubMed
    74. Quinn D, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417; PMCID: PMC4277263.
    75. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn D. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. PMID: 23785174; PMCID: PMC3783857.
    76. Hepgur M, Sadeghi S, Dorff TB, Quinn D. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. PMID: 23788831; PMCID: PMC3684142.
    77. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn D, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. PMID: 23550669; PMCID: PMC3682658.
    78. Pal SK, Quinn D. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013 Nov; 39(7):709-19. PMID: 23433636; PMCID: PMC4957946.
    79. Feldman DR, Einhorn LH, Quinn D, Loriot Y, Joffe JK, Vaughn DJ, Fléchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013 Aug; 31(4):1016-22. PMID: 23417696.
      View in: PubMed
    80. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn D, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013 Jan 01; 31(1):131-61. PMID: 23213095.
      View in: PubMed
    81. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. PMID: 23141776.
      View in: PubMed
    82. Fahed E, Hansel DE, Raghavan D, Quinn D, Dorff TB. Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. PMID: 23040258.
      View in: PubMed
    83. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn D. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012 Oct; 13(10):1055-62. PMID: 22959186.
      View in: PubMed
    84. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn D. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. PMID: 22917984.
      View in: PubMed
    85. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn D. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503; PMCID: PMC3375600.
    86. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn D, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
    87. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn D. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr 18; 4(2):420-41. PMID: 24213318; PMCID: PMC3712699.
    88. Zhang SY, Thara E, Quinn D, Dorff TB. Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr; 8(4):528-33. PMID: 22370509.
      View in: PubMed
    89. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn D. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther. 2012 Mar; 11(3):526-37. PMID: 22351744; PMCID: PMC3297694.
    90. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn D, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12. PMID: 22184381; PMCID: PMC4104290.
    91. Armstrong AJ, Ferrari AC, Quinn D. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec; 9(12 Suppl 28):1-14; quiz 15-6. PMID: 22407145.
      View in: PubMed
    92. Desai B, Elatre W, Quinn D, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. PMID: 21892064; PMCID: PMC3167095.
    93. Mitra AP, Quinn D, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. PMID: 21812902.
      View in: PubMed
    94. Thara E, Dorff TB, Pinski JK, Quinn D. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. PMID: 21621934.
      View in: PubMed
    95. Swanson GP, Quinn D. Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer. 2011; 2011:290160. PMID: 22096655; PMCID: PMC3200300.
    96. Shek D, Longmate J, Quinn D, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. PMID: 21431345.
      View in: PubMed
    97. Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. PMID: 21310657.
      View in: PubMed
    98. Ell K, Xie B, Kapetanovic S, Quinn D, Lee PJ, Wells A, Chou CP. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv. 2011 Feb; 62(2):162-70. PMID: 21285094.
      View in: PubMed
    99. Iqbal S, Tsao-Wei DD, Quinn D, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
      View in: PubMed
    100. Dorff TB, Quinn D. Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 02; 376(9747):1119-20. PMID: 20888974.
      View in: PubMed
    101. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn D, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741; PMCID: PMC2952720.
    102. Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. PMID: 20553208.
      View in: PubMed
    103. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn D, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019; PMCID: PMC2898710.
    104. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. PMID: 20399677.
      View in: PubMed
    105. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec 31; 1(12):988-1007. PMID: 20157582; PMCID: PMC2815756.
    106. Dorff TB, Quinn D. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. PMID: 19645028.
      View in: PubMed
    107. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn D, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. PMID: 19884559; PMCID: PMC2793000.
    108. Dorff TB, Goldkorn A, Quinn D. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. PMID: 21789121; PMCID: PMC3125999.
    109. Lara PN, Longmate J, Evans CP, Quinn D, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016; PMCID: PMC3225398.
    110. Cheung E, Pinski J, Dorff T, Groshen S, Quinn D, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    111. Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn D, Vogelzang NJ, Thompson IM, Hussain MH. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. PMID: 21085622.
      View in: PubMed
    112. Quinn D, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 2009; 48(3):199-209. PMID: 19385713.
      View in: PubMed
    113. Dorff TB, Tsao-Wei D, Miranda G, Skinner DG, Stein JP, Quinn D. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. PMID: 19020886.
      View in: PubMed
    114. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn D, Beekman K, Montie JE. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. PMID: 18930256; PMCID: PMC2716704.
    115. Ell K, Xie B, Quon B, Quinn D, Dwight-Johnson M, Lee PJ. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol. 2008 Sep 20; 26(27):4488-96. PMID: 18802161; PMCID: PMC2653113.
    116. Chan JS, Beer TM, Quinn D, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. PMID: 18782306.
      View in: PubMed
    117. Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn D, Liebman HA. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. PMID: 18671791.
      View in: PubMed
    118. Chee KG, Longmate J, Quinn D, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    119. Stadler WM, Desai AA, Quinn D, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. PMID: 17569043.
      View in: PubMed
    120. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn D, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. PMID: 17508219.
      View in: PubMed
    121. Ell K, Quon B, Quinn D, Dwight-Johnson M, Wells A, Lee PJ, Xie B. Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. PMID: 17484939; PMCID: PMC1868447.
    122. Turner JS, Cheung EM, George J, Quinn D. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1305-12. PMID: 17441929.
      View in: PubMed
    123. Henshall SM, Horvath LG, Quinn D, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006 Oct 04; 98(19):1420-4. PMID: 17018789.
      View in: PubMed
    124. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn D, Raghavan D, Crawford ED. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15; 106(12):2624-9. PMID: 16688776.
      View in: PubMed
    125. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn D, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. PMID: 16515971.
      View in: PubMed
    126. Levine AM, Tulpule A, Quinn D, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. PMID: 16520466.
      View in: PubMed
    127. Lara PN, Stadler WM, Longmate J, Quinn D, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      View in: PubMed
    128. Lara PN, Koczywas M, Quinn D, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
      View in: PubMed
    129. Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. PMID: 16379039.
      View in: PubMed
    130. Hutson TE, Quinn D. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6. PMID: 16425986.
      View in: PubMed
    131. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn D, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. PMID: 16221056.
      View in: PubMed
    132. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn D, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. PMID: 16020668.
      View in: PubMed
    133. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. PMID: 15958611.
      View in: PubMed
    134. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn D, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. PMID: 15930280.
      View in: PubMed
    135. Aparicio AM, Elkhouiery AB, Quinn D. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am. 2005 May; 32(2):217-30, vii. PMID: 15862619.
      View in: PubMed
    136. Buscarini M, Quek ML, Gill P, Xia G, Quinn D, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. PMID: 15794774.
      View in: PubMed
    137. Quinn D, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005 Apr; 41(6):858-87. PMID: 15808955.
      View in: PubMed
    138. Lara PN, Twardowski P, Quinn D. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. PMID: 15636683.
      View in: PubMed
    139. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, Millar JL, Brew BJ, Quinn D. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 Jun 15; 100(12):2627-36. PMID: 15197806.
      View in: PubMed
    140. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn D, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. PMID: 14713777.
      View in: PubMed
    141. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6. PMID: 14713788.
      View in: PubMed
    142. Quinn D. The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44. PMID: 16985929; PMCID: PMC1472936.
    143. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003 Nov; 170(5):1798-803. PMID: 14532779.
      View in: PubMed
    144. Lara PN, Quinn D, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
      View in: PubMed
    145. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn D, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene. 2003 Sep 04; 22(38):6005-12. PMID: 12955079.
      View in: PubMed
    146. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn D, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61. PMID: 12942562.
      View in: PubMed
    147. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn D, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. PMID: 12874026.
      View in: PubMed
    148. Quinn D, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003 Apr 15; 97(8):1884-93. PMID: 12673714.
      View in: PubMed
    149. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn D, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3410-5. PMID: 12624183; PMCID: PMC152306.
    150. Graefen M, Karakiewicz PI, Cagiannos I, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002 Aug 01; 20(15):3206-12. PMID: 12149292.
      View in: PubMed
    151. Raghavan D, Quinn D, Skinner DG, Stein JP. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol. 2002 Jun; 11(1-2):55-63. PMID: 12031868.
      View in: PubMed
    152. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002 Feb 15; 20(4):951-6. PMID: 11844816.
      View in: PubMed